Oncomine Myeloid Panel for MDS, MPN, AML, CML, CMML, JMML
Comprehensive Genetic Analysis for Myeloid Malignancies
The Oncomine Myeloid Panel represents a cutting-edge diagnostic advancement in hematologic oncology, providing comprehensive genetic profiling for patients with suspected or confirmed myeloid malignancies. This next-generation sequencing (NGS) test offers unparalleled insights into the genetic landscape of various blood cancers, enabling precise diagnosis and personalized treatment approaches.
What Does the Oncomine Myeloid Panel Detect?
This sophisticated genetic test analyzes multiple key genes associated with myeloid malignancies, including:
- MDS (Myelodysplastic Syndromes) – Detects mutations in genes like TP53, RUNX1, ASXL1, and others
- MPN (Myeloproliferative Neoplasms) – Identifies JAK2, CALR, and MPL mutations
- AML (Acute Myeloid Leukemia) – Screens for FLT3, NPM1, CEBPA, and IDH1/2 mutations
- CML (Chronic Myeloid Leukemia) – Monitors BCR-ABL1 fusion and resistance mutations
- CMML (Chronic Myelomonocytic Leukemia) – Detects TET2, SRSF2, and ASXL1 mutations
- JMML (Juvenile Myelomonocytic Leukemia) – Identifies PTPN11, NRAS, KRAS, and NF1 mutations
Who Should Consider This Test?
The Oncomine Myeloid Panel is recommended for individuals experiencing:
- Unexplained cytopenias (low blood counts)
- Abnormal blood cell morphology
- Splenomegaly or hepatomegaly
- Constitutional symptoms like fatigue, fever, or night sweats
- Family history of hematologic malignancies
- Monitoring treatment response in known myeloid disorders
- Evaluation of unexplained peripheral blood abnormalities
Key Benefits of the Oncomine Myeloid Panel
- Comprehensive Analysis: Simultaneous evaluation of multiple genetic markers
- Precision Diagnosis: Accurate classification of myeloid malignancies
- Treatment Guidance: Identifies targetable mutations for personalized therapy
- Prognostic Information: Provides risk stratification and outcome prediction
- Minimal Sample Requirement: Requires only bone marrow or peripheral blood
- Rapid Turnaround: Results available within 2-3 weeks
Understanding Your Test Results
Your Oncomine Myeloid Panel results will provide detailed information about detected genetic mutations. Positive results indicate specific genetic alterations that may guide treatment decisions. Negative results suggest the absence of commonly tested mutations, though additional testing may be recommended based on clinical presentation. Our genetic counselors and hematology specialists will help interpret your results and discuss appropriate next steps for your care.
Test Pricing and Details
| Test Component | Details |
|---|---|
| Test Name | Oncomine Myeloid Panel for MDS, MPN, AML, CML, CMML, JMML |
| Discount Price | $938 USD |
| Regular Price | $1250 USD |
| Turnaround Time | 2-3 weeks |
| Sample Type | Bone marrow / Peripheral blood |
| Test Components | Sodium Heparin Vacutainer (2ml) & EDTA Vacutainer (3ml) |
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our state-of-the-art facilities ensure consistent, high-quality testing services nationwide.
Book Your Test Today
Take the first step toward precise diagnosis and personalized treatment. Our experienced team is ready to assist you with scheduling and answer any questions about the Oncomine Myeloid Panel. Contact us today to schedule your appointment and begin your journey toward comprehensive genetic analysis.
Call or WhatsApp: +1(267) 388-9828
Note: This test requires a doctor’s prescription. Prescription requirements do not apply to surgery and pregnancy cases or individuals planning international travel.
